| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.22 | 0.01 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.02 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.097 | 0.02 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.094 | 0.02 |